Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis

American Surgeon

Volumn 79, Issue 6, 2013, Pages 620-624

  Randle, Reese W ^a   Swett, Katrina R ^b   Shen, Perry ^a   Stewart, John H ^a   Levine, Edward A ^a   Votanopoulos, Konstantinos I ^a  

^a Surgical Oncology   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOMYCIN; MITOXANTRONE;

ADULT; AGED; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY WITH HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PERITONEAL SARCOMATOSIS; PERITONEUM CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PERITONEUM; RETROSPECTIVE STUDIES; SARCOMA;

EID: 84878252064     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Singer S, Maki RG, O'Sullivan B. Soft tissue sarcoma. In: De Vita VT Jr, Lawrence TS, Rosenberg SA, et al., eds. Cancer: Principles & Practice of Oncology. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011:1533-77.
3. Mudan SS, Conlon KC, Woodruff JM, et al. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000;88:66-74.
4. Rossi CR, Deraco M, De SM, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients. Cancer 2004;100:1943-50.
5. Lim SJ, Cormier JN, Feig BW, et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol 2007;14:2309-18.
6. Karakousis CP, Blumenson LE, Canavese G, et al. Surgery for disseminated abdominal sarcoma. Am J Surg 1992;163:560-4.
7. Bilimoria MM, Holtz DJ, Mirza NQ, et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer 2002;94:2441-6.
8. Levine EA, Stewart JH, Russell GB, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg 2007;204:943-53.
9. Gusani NJ, Cho SW, Colovos C, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008;15:754-63.
10. Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1, 290 patients. Cancer 2010;116:5608-18.
11. Chua TC, Liauw W, Saxena A, et al. Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Am J Surg 2011;201:149-56.
12. Bonvalot S, Cavalcanti A, Le PC, et al. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur J Surg Oncol 2005;31:917-23.
13. Baratti D, Pennacchioli E, Kusamura S, et al. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol 2010;17:3220-8.
14. Huh WW, Fitzgerald NE, Mahajan A, et al. Peritoneal sarcomatosis in pediatric malignancies. Pediatr Blood Cancer 2013;60:12-7.
15. Munene G, Mack LA, Temple WJ. Systematic review on the efficacy of multimodal treatment of sarcomatosis with cytoreduction and intraperitoneal chemotherapy. Ann Surg Oncol 2011;18:207-13.
16. Rossi CR, Casali P, Kusamura S, et al. The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol 2008;98:291-4.
17. Sugarbaker PH. Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol 2001;31:573-83.
18. Berthet B, Sugarbaker TA, Chang D, et al. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer 1999;35:413-9.
19. Hill AR, McQuellon RP, Russell GB, et al. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol 2011;18:3673-9.
20. McQuellon RP, Danhauer SC, Russell GB, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2007;14:1105-13.
21. Tsilimparis N, Bockelmann C, Raue W, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol 2013;20:226-32.
22. Salti GI, Ailabouni L, Undevia S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis. Ann Surg Oncol 2012;19:1410-5.
23. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.